<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lensar Inc — News on 6ix</title>
<link>https://6ix.com/company/lensar-inc</link>
<description>Latest news and press releases for Lensar Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 31 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lensar-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683592d378dffbe2df1030a8.webp</url>
<title>Lensar Inc</title>
<link>https://6ix.com/company/lensar-inc</link>
</image>
<item>
<title>LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update</title>
<link>https://6ix.com/company/lensar-inc/news/lensarr-reports-fourth-quarter-and-full-year-2025-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/lensarr-reports-fourth-quarter-and-full-year-2025-results-and-provides-business-update</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>15 ALLY Robotic Cataract Laser Systems® (“ALLY Systems”) placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025 ALLY</description>
</item>
<item>
<title>LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC</title>
<link>https://6ix.com/company/lensar-inc/news/lensarr-announces-termination-of-merger-agreement-with-alcon-research-llc</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/lensarr-announces-termination-of-merger-agreement-with-alcon-research-llc</guid>
<pubDate>Mon, 16 Mar 2026 20:30:00 GMT</pubDate>
<description>Company to Report Fourth Quarter Financial Results and Provide Strategic Update on March 31, 2026ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, announced that it reached an agreement with Alcon Research, LLC (“Alcon”) to terminate the merger agreement between the parties. We understand that the Federal Trade Commission intends</description>
</item>
<item>
<title>Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement</title>
<link>https://6ix.com/company/lensar-inc/news/alcon-and-lensar-inc-agree-to-terminate-merger-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/alcon-and-lensar-inc-agree-to-terminate-merger-agreement</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has</description>
</item>
<item>
<title>LENSAR® Provides Update on Pending Acquisition by Alcon</title>
<link>https://6ix.com/company/lensar-inc/news/lensarr-provides-update-on-pending-acquisition-by-alcon</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/lensarr-provides-update-on-pending-acquisition-by-alcon</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>ORLANDO, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on</description>
</item>
<item>
<title>LENSAR® Reports Third Quarter 2025 Results and Provides Business Update</title>
<link>https://6ix.com/company/lensar-inc/news/lensar-reports-third-quarter-2025-120000203</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/lensar-reports-third-quarter-2025-120000203</guid>
<pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
<description>18 ALLY Robotic Cataract Laser Systems® (“ALLY Systems”) placed in 3Q 2025; Backlog of 18 ALLY Systems pending installation as of September 30, 2025 ALLY installed base grew 77% and total laser installed base grew 20% over 3Q 2024 ORLANDO, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter e</description>
</item>
<item>
<title>LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/lensar-inc/news/lensar-reports-inducement-grants-under-200100909</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/lensar-reports-inducement-grants-under-200100909</guid>
<pubDate>Tue, 02 Sep 2025 20:01:00 GMT</pubDate>
<description>ORLANDO, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units (“RSUs”). The RSUs were granted as of September 2, 2025, as inducement for each such employee commencing employment with the Company. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Each</description>
</item>
<item>
<title>LENSAR Reports Second Quarter 2025 Results and Provides Business Update</title>
<link>https://6ix.com/company/lensar-inc/news/lensar-reports-second-quarter-2025-110000113</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/lensar-reports-second-quarter-2025-110000113</guid>
<pubDate>Thu, 07 Aug 2025 11:00:00 GMT</pubDate>
<description>18 ALLY Robotic Cataract Laser Systems™ (“ALLY Systems”) placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of</description>
</item>
<item>
<title>LENSAR Reports First Quarter 2025 Results and Provides Business Update</title>
<link>https://6ix.com/company/lensar-inc/news/lensar-reports-first-quarter-2025-110000305</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/lensar-reports-first-quarter-2025-110000305</guid>
<pubDate>Thu, 08 May 2025 11:00:00 GMT</pubDate>
<description>14 ALLY Robotic Laser Cataract Systems™ (“ALLY Systems”) placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over the first quarter of 2024 ORLANDO, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company), a global medical technology company focused on advanced</description>
</item>
<item>
<title>Alcon Agrees to Acquire LENSAR, Inc.</title>
<link>https://6ix.com/company/lensar-inc/news/alcon-agrees-to-acquire-lensar-inc</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/alcon-agrees-to-acquire-lensar-inc</guid>
<pubDate>Mon, 24 Mar 2025 04:00:00 GMT</pubDate>
<description>Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon’s cataract equipment and technology portfolio Next generation technology will be</description>
</item>
<item>
<title>LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update</title>
<link>https://6ix.com/company/lensar-inc/news/lensar-reports-fourth-quarter-full-120000426</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/lensar-reports-fourth-quarter-full-120000426</guid>
<pubDate>Thu, 27 Feb 2025 12:00:00 GMT</pubDate>
<description>31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company’s total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE)</description>
</item>
<item>
<title>LENSAR to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 27, 2025</title>
<link>https://6ix.com/company/lensar-inc/news/lensar-to-report-fourth-quarter-and-full-year-2024-financial-results-on-thursday-february-27-2025</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/lensar-to-report-fourth-quarter-and-full-year-2024-financial-results-on-thursday-february-27-2025</guid>
<pubDate>Wed, 19 Feb 2025 05:00:00 GMT</pubDate>
<description>ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on</description>
</item>
<item>
<title>LENSAR to Participate in the BTIG 4th Annual Ophthalmology Day</title>
<link>https://6ix.com/company/lensar-inc/news/lensar-to-participate-in-the-btig-4th-annual-ophthalmology-day</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/lensar-to-participate-in-the-btig-4th-annual-ophthalmology-day</guid>
<pubDate>Tue, 26 Nov 2024 05:00:00 GMT</pubDate>
<description>ORLANDO, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on</description>
</item>
<item>
<title>LENSAR Reports Third Quarter 2024 Results and Provides Business Update</title>
<link>https://6ix.com/company/lensar-inc/news/lensar-reports-third-quarter-2024-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/lensar-reports-third-quarter-2024-results-and-provides-business-update</guid>
<pubDate>Thu, 07 Nov 2024 05:00:00 GMT</pubDate>
<description>24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as</description>
</item>
<item>
<title>LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024</title>
<link>https://6ix.com/company/lensar-inc/news/lensar-to-report-third-quarter-2024-financial-results-on-thursday-november-7-2024</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/lensar-to-report-third-quarter-2024-financial-results-on-thursday-november-7-2024</guid>
<pubDate>Thu, 31 Oct 2024 04:00:00 GMT</pubDate>
<description>ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on</description>
</item>
<item>
<title>One Millionth Procedure Completed Using LENSAR’s Cataract Laser Systems</title>
<link>https://6ix.com/company/lensar-inc/news/one-millionth-procedure-completed-using-lensars-cataract-laser-systems</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/one-millionth-procedure-completed-using-lensars-cataract-laser-systems</guid>
<pubDate>Tue, 08 Oct 2024 04:00:00 GMT</pubDate>
<description>ORLANDO, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on</description>
</item>
<item>
<title>LENSAR to Participate in Two Upcoming Investor Conferences</title>
<link>https://6ix.com/company/lensar-inc/news/lensar-to-participate-in-two-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/lensar-to-participate-in-two-upcoming-investor-conferences</guid>
<pubDate>Wed, 04 Sep 2024 04:00:00 GMT</pubDate>
<description>ORLANDO, Fla.--(BUSINESS WIRE)-- LENSAR®, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser</description>
</item>
<item>
<title>LENSAR Reports Second Quarter 2024 Results and Provides Business Update</title>
<link>https://6ix.com/company/lensar-inc/news/lensar-reports-second-quarter-2024-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/lensar-reports-second-quarter-2024-results-and-provides-business-update</guid>
<pubDate>Thu, 08 Aug 2024 04:00:00 GMT</pubDate>
<description>17 New ALLY® Adaptive Cataract Treatment Systems placed in 2Q 2024; highest number of placements since launch Received Medical Device Regulation (MDR)</description>
</item>
<item>
<title>LENSAR Announces Certification for the ALLY® Adaptive Cataract Treatment System in the European Union</title>
<link>https://6ix.com/company/lensar-inc/news/lensar-announces-certification-for-the-allyr-adaptive-cataract-treatment-system-in-the-european-union</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/lensar-announces-certification-for-the-allyr-adaptive-cataract-treatment-system-in-the-european-union</guid>
<pubDate>Wed, 07 Aug 2024 04:00:00 GMT</pubDate>
<description>First EU ALLY Commercial Installation Planned for August 2024 ORLANDO, Fla.--(BUSINESS WIRE)-- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a</description>
</item>
<item>
<title>LENSAR to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024</title>
<link>https://6ix.com/company/lensar-inc/news/lensar-to-report-second-quarter-2024-financial-results-on-thursday-august-8-2024</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/lensar-to-report-second-quarter-2024-financial-results-on-thursday-august-8-2024</guid>
<pubDate>Thu, 01 Aug 2024 04:00:00 GMT</pubDate>
<description>ORLANDO, Fla.--(BUSINESS WIRE)-- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser</description>
</item>
<item>
<title>LENSAR to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference</title>
<link>https://6ix.com/company/lensar-inc/news/lensar-to-participate-in-the-2024-leerink-partners-healthcare-crossroads-conference</link>
<guid isPermaLink="true">https://6ix.com/company/lensar-inc/news/lensar-to-participate-in-the-2024-leerink-partners-healthcare-crossroads-conference</guid>
<pubDate>Thu, 23 May 2024 04:00:00 GMT</pubDate>
<description>ORLANDO, Fla.--(BUSINESS WIRE)-- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond</description>
</item>
</channel>
</rss>